Optimising Pacing for Contractility 2

Recruiting Phase 2 Phase 3 Interventional Study
Heart Failure, Systolic Pacemaker
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2/3
Study type
Interventional
Purpose
Treatment
Participants needed
400 (estimated)
Sponsor
University of Leeds · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The investigators have demonstrated that they can reliably identify an optimum heart rate range for contractility of the left ventricle in patients with chronic heart failure (CHF). They have also demonstrated in an acute cross-over and a small parallel group feasibility study that keeping the heart rate in this range (versus standard rate-response programming) in patients with CHF is associated w…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Clinical, echocardiographic and neurohormonal evidence of heart failure * Cardiac pacemaker, * Able to perform a peak exercise test, * Willing and able to give informed consent. Exclusion Criteria: * Angina pectoris symptoms limiting exercise tolerance, * Unstable heart fail…
Contacts

Klaus K Witte, MD

01133926642

k.k.witte@leeds.ac.uk

CONTACT

Klaus Witte

01133926642

k.k.witte@leeds.ac.uk

CONTACT